Skip to main content

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  

Continue reading

Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Richard Newcomb, Hematology/Oncology Fellow at Dana-Farber/Mass General Cancer Center, sat down with Oncology Data Advisor to elaborate on his study regarding uncertainty and coping experienced by patients with newly diagnosed indolent non-Hodgkin lymphoma (NHL), as well as strategies for supporting patients facing distress around their diagnosis.  

Continue reading

Increasing Expertise for Treatment of Non-Hodgkin Lymphoma

An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American Cancer Society estimated that 80,470 new diagnoses of NHL will occur in 2022, with 20,250 resulting in death. Aggressive subtypes, including diffuse ...

Continue reading

i3 Health Presents Oncology Nursing Showdown: Non-Hodgkin Lymphoma Edition at Oncology Nursing Society Congress

i3 Health's study focusing on the effectiveness of a nursing continuing professional development (NCPD)–approved activity to improve clinicians' knowledge of the individualized treatment of patients with non-Hodgkin lymphoma (NHL) has been published as a 47th Annual Oncology Nursing Society (ONS) Congress online abstract. The abstract, authored by Elizabeth Heller, PhD; Keira Smith, BA; Kristin Wright, PharmD; and Sarah Williams, MAT, of i3 Health, and Maria Badillo, MSN, RN, OCN®, CCRP, Researc...

Continue reading

Oncology Showdown Activity Tackles Proficiency in Treatment of Advanced Non-Hodgkin Lymphoma

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

Continue reading

Interpreting the CAR T Results of Tisagenlecleucel for Relapsed/Refractory Non-Hodgkin Lymphoma: Michael R. Bishop, MD

Michael Bishop, MD.

In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.  

Continue reading

FDA Approves Zanubrutinib for Waldenstrom Macroglobulinemia

The FDA has granted approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with Waldenstrom macroglobulinemia (WM). "Bruton tyrosine kinase (BTK) inhibition is an emerging standard of care for WM," wrote Constantine Si Lun Tam, MBBS, MD, FRACP, FRCPA, Professor at the Peter MacCallum Cancer Centre in Australia, and colleagues, in their publication of the ASPEN study results (NCT03053440), on which the approval was based. "ASPEN is a randomized phase 3 study comparing zanubru...

Continue reading

Caring for Patients With Aggressive Non-Hodgkin Lymphoma: Maria R. Badillo, MSN, RN, OCN®, CCRP

Non-Hodgkin lymphoma (NHL) is one of the most common cancers, comprising 4% of all cancers in the United States. Although non-Hodgkin lymphoma can occur at any age, more than half of all patients are 65 years old or older. Efforts are ongoing to find new and better ways to treat non-Hodgkin lymphoma. In this interview, Maria Badillo, MSN, RN, OCN®, CCRP, a Research Nurse Manager at The University of Texas MD Anderson Cancer Center, talks about the challenges and strategies involving the nursing ...

Continue reading

FDA Approves Axicabtagene Ciloleucel for Relapsed/Refractory Follicular Lymphoma

The FDA has granted accelerated approval to axicabtagene ciloleucel (Yescarta®, Kite Pharma, Inc.) for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. An indolent form of non-Hodgkin lymphoma (NHL) that is not generally curable, FL is considered a chronic disease. Therefore, people living with FL often require second-line therapies after their di...

Continue reading

Knowledge Gaps Revealed in Waldenström Macroglobulinemia

Waldenström macroglobulinemia is a rare lymphoproliferative disorder, with an estimated 1,500 new cases reported in the United States each year. This malignancy, which accounts for 2% of non-Hodgkin lymphomas, is characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM). It is important for health care professionals involved in the care of patients with Waldenström macroglobulinemia to remain up to date in their knowledge of risk stra...

Continue reading

DLBCL: Complete Surgical Resection Before Immunochemotherapy May Benefit Younger Patients

Complete surgical resection prior to immunochemotherapy may benefit patients with diffuse large B-cell lymphoma (DLBCL) under the age of 60, according to results from a subgroup analysis of the phase 3 PETAL trial. Unlike the treatment of solid tumors, the treatment of lymphoma focuses almost exclusively on systemic therapy. Surgical resection is generally only performed for diagnostic value, and little evidence exists regarding its impact on outcomes for patients with lymphoma. "Modern imaging ...

Continue reading

To Fight Cancer, Grow T Cells in a Lab

Researchers at the University of California, Los Angeles (UCLA) have become the first to successfully develop mature, cancer-killing T cells in a laboratory setting. The immune system's T cells fight infections; they also have the ability to fight cancer. Therapies that involve genetically engineering a patient's own T cells with a receptor that helps the T cells to recognize and destroy cancer cells have tremendous potential for certain types of cancer. One of these therapies is CAR T-cell ther...

Continue reading

Glyphosate-Based Herbicides Linked to Non-Hodgkin Lymphoma

Researchers report that glyphosate, the herbicide commonly found in Roundup® (Monsanto Technology, LLC), which is used as a pesticide on produce, significantly increases the risk of developing non-Hodgkin lymphoma (NHL) in humans. "Our analysis focused on providing the best possible answer to the question of whether or not glyphosate is carcinogenic," remarked the senior author of the paper, Lianne Sheppard, PhD, Professor of Environmental and Occupational Health Sciences and Biostatistics at th...

Continue reading

Glyphosate-Based Herbicides Increase Cancer Risk: An Interview With Luoping Zhang, PhD, MS

Glyphosate-based herbicides, such as Roundup®, are widely used in the United States in crops, gardens, and lawncare. Luoping Zhang, PhD, MS, Adjunct Professor at University of California, Berkeley, and colleagues revealed in a study that exposure to glyphosate increases an individual's chance of developing non-Hodgkin lymphoma (NHL). In this interview with i3 Health, Dr. Zhang shared insights about the implications of exposure to glyphosate-based herbicides and recommendations for avoiding expos...

Continue reading